# United Therapeutics Corporation (UTHR)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $26.06B  
**Price:** $544.10 (-1.63%)

> United Therapeutics Corporation is a biotechnology company specializing in therapies for pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease, and other serious conditions. Founded in 1996 and headquartered in Silver Spring, Maryland, the company operates as a public benefit corporation focused on developing innovative treatments and technologies. Its FDA-approved therapeutic portfolio includes Tyvaso (treprostinil), available in both inhalation powder and nebulized formulations; Remodulin Injection; Orenitram Extended-Release Tablets; Adcirca (tadalafil); and Unituxin for treating PAH and related conditions. Beyond traditional pharmaceuticals, United Therapeutics pursues transformational initiatives through its subsidiary Lung Biotechnology PBC to address the critical shortage of transplantable organs through xenotransplantation and bioengineering technologies. The company maintains a robust commercial presence, distributing products through healthcare provider networks and partnerships. Its pipeline includes clinical programs exploring new therapeutic indications, delivery mechanisms, and organ manufacturing solutions. United Therapeutics serves patients, healthcare providers, and research institutions globally, combining steady commercial performance with visionary medical innovation.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $3.18B | $2.80B | $1.49B | $1.33B | — |
| 2024 | $2.88B | $2.57B | $1.38B | $1.20B | — |
| 2023 | $2.33B | $2.07B | $1.18B | $985M | — |
| 2022 | $1.94B | $1.78B | $980M | $727M | — |
| 2021 | $1.69B | $1.56B | $556M | $476M | — |
| 2020 | $1.48B | $1.38B | $594M | — | — |
| 2019 | $1.45B | $1.33B | -$188M | — | — |
| 2018 | $1.63B | — | $805M | — | — |
| 2017 | $1.73B | — | $815M | — | — |
| 2016 | $1.60B | — | $1.06B | — | — |
| 2015 | $1.47B | — | $699M | — | — |
| 2014 | $1.29B | $1.15B | $539M | — | — |
| 2013 | $1.12B | $976M | $292M | — | — |
| 2012 | $916M | $787M | $422M | — | — |
| 2011 | $743M | $652M | $318M | — | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $7.88B | $784M | $7.10B | $1.56B | — |
| 2024 | $7.36B | $920M | $6.44B | $1.70B | — |
| 2023 | $7.17B | $1.18B | $5.98B | $1.21B | — |
| 2022 | $6.04B | $1.25B | $4.80B | $961M | — |
| 2021 | $5.17B | $1.21B | $3.96B | $895M | — |
| 2020 | $4.62B | $1.22B | $3.40B | $739M | — |
| 2019 | $3.91B | $1.13B | $2.78B | $738M | — |
| 2018 | $3.40B | $593M | $2.79B | $669M | — |
| 2017 | $2.88B | $758M | $2.10B | $705M | — |
| 2016 | $2.33B | $463M | $1.85B | $1.02B | — |
| 2015 | $2.18B | $585M | $1.59B | $832M | — |
| 2014 | $1.88B | $619M | $1.24B | $398M | — |
| 2013 | $2.09B | $783M | $1.26B | $284M | — |
| 2012 | $1.63B | $532M | $1.08B | $159M | — |
| 2011 | $1.52B | $559M | $948M | $168M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $1.56B | $521M | $1.04B |
| 2024 | $1.33B | $247M | $1.08B |
| 2023 | $978M | $230M | $748M |
| 2022 | $803M | $139M | $664M |
| 2021 | $598M | $121M | $477M |
| 2020 | $756M | $59M | $696M |
| 2019 | -$207M | $84M | -$290M |
| 2018 | $778M | $184M | $594M |
| 2017 | $474M | $86M | $388M |
| 2016 | $644M | $38M | $606M |
| 2015 | $383M | $50M | $333M |
| 2012 | $324M | $112M | $212M |
| 2011 | $250M | $36M | $214M |
| 2010 | $212M | $19M | $193M |
| 2009 | $100M | $95M | $4M |

Source: [CompaniesByCap](https://companiesbycap.com/company/UTHR)